Effect of vaginal/oral tadalafil on endometrial thickness in IVF patients: a double-blind, placebo controlled RCT: a pilot study
PDF
Cite
Share
Request
Original Articles
VOLUME: 14 ISSUE: 2
P: 155 - 161
June 2022

Effect of vaginal/oral tadalafil on endometrial thickness in IVF patients: a double-blind, placebo controlled RCT: a pilot study

Facts Views Vis ObGyn 2022;14(2):155-161
1. KU Leuven, Resident Obstetrics and Gynaecology, Oude Markt 13, 3000 Leuven, Belgium
2. Fertility Center, Department of Obstetrics and Gynaecology, AZ Jan Palfijn, Henri Dunantlaan 5, 9000 Ghent, Belgium
No information available.
No information available
PDF
Cite
Share
Request

Abstract

Objective

To investigate the effect of tadalafil (a long working phosphodiesterase type 5 inhibitor) on the endometrial thickness, biochemical pregnancy rates and clinical pregnancy rates in women in an in vitro fertilization treatment. This study investigates the use of vaginal and oral administration of tadalafil.

Study design

This is a prospective double-blind placebo-controlled randomized controlled trial with 58 patients in an in vitro fertilization treatment with a short antagonist stimulation protocol. The study population is divided into three equal groups comparing oral and vaginal administration of tadalafil to a control group.

Results

No significant difference in endometrial thickness and number of biochemical and clinical pregnancies was found between the three groups.

Conclusion

This study could not show a significant benefit of administration of tadalafil. However, a trend towards more pregnancies in the group treated with oral tadalafil is seen, more research in specific subgroups is needed.

Keywords:
Tadalafil, endometrial thickness, implantation, oral/vaginal application